semaglutide is a Peptide of the Week: Peptide: Promising Advancement in Diabetes Treatment Semaglutide GLP-1 Treatment Specialist |

Sweating accompanied by signs of hypoglycemia (low blood sugar) requires immediate attention, particularly if you are taking Zepbound in combination with insulin or insulin secretagogues such as sulfonylureas

Although rare, pancreatitis is a recognised serious adverse effect of GLP-1 receptor agonists

Obesity may present challenges , but you are so much more than a number on a scale

The medication may simultaneously slow food transit and increase the bacterial population responsible for sulfur gas production

This may include delaying decisions about food, substituting high calorie snacks with lighter options, improving hydration, or using distraction techniques such as walking, stretching, or starting a brief task